unresectable advanced colorectal cancer
Conditions
Interventions
panitumumab+skin moisturizers(8weeks)
panitumumab+skinmoisturizers+sunscreen+minocycline+topical steroid(8weeks)
Sponsors
Hokkaido Gastrointestinal Cancer Study Group(HGCSG)
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Histologically confirmed adenocarcinoma of the colon and rectum 2. KRAS wild type 3. Patients failed to second line treatment with confirmed target lesion 4. ECOG performance status of 0,1,2 5. Life expectancy of longer than 3 months 6. Written informed consent 7.Good function of critical organs WBC>=3,000/mm3 (neutrophil>=1,500) Platelets>=75,000/mm3 Hemoglobin>=8.0g/dl Total bilirubin<=1.5x each hospitals criteria AST/ALT/ALP<=2.5x each hospitals criteria(liver/bone metastasis<=5xeach hospitals criteria) Creatinine<=2.0x each hospitals criteria
Exclusion criteria
Exclusion criteria: (a)Patient who have previous history of hypersensitivity in Panitumumab and other medicines (b)The KRAS mutation type. (c)pregnant woman or possibility pregnancy while suckling walking (d)Patient with interstitial pneumonia (e)the anti-EGFR antibody had been administered so far. (f)Patient who is administering bevacizumab (g)Patient who is judged improper by Doctor.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Adverce event of skin toxicity (>= grade2) during the 6 weeks from treatment started | — |
Secondary
| Measure | Time frame |
|---|---|
| Time to appearance of skin toxicity(each grade) ,Safety,Progression-free Survival, Overall Survival,Time-to-treatment-failure,Overall Response Rate | — |
Countries
Japan
Contacts
Public ContactYoshimitsu Kobayashi
Hokkaido University Hospital Cancer Center
Outcome results
None listed